Enbrel

Type: Product
Name: Enbrel
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Systemic Treatment and Cardiovascular Risk Markers in Psoriasis

Reuters Health InformationBy Will Boggs MDApril 14, 2014NEW YORK (Reuters Health) - Systemic treatment is associated with improved cardiovascular risk markers in patients with psoriasis, whereas narrowband ultraviolet B (UVB) is not, researchers from ... [Published American Journal of Public Health - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Chinese Thunder God Herb Works as Well as Pain Therapy...

Thunder god vine could become a new approach to treating rheumatoid arthritis because not all patients respond to methotrexate and modern biologic treatments, such as Amgen Inc.’s Enbrel, are expensive, the researchers wrote in the report. “While the ... [Published Atlanta Journal And Constitution - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

The Skin You're In

accutane acne adult acne antibiotics antibotic resistance athlete's foot bartender's detmatitis chiggers dermatology diet and acne disease modifying drugs eczema enbrel humire hydration isotretinoin itch itching itching and pain laser treatment lymphoma ... [Published EverydayHealth.com - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Biotech firms, investors biding time for breakthrough drugs

Windsor Genova – Fourth Estate Cooperative ContributorNew York, NY, United States (4E) – Many biotech firms are now biding their time, waiting for their research projects to result in a breakthrough drug that will not only cure a once untreatable disease ... [Published GantDaily.com - Apr 14 2014]
First reported Apr 13 2014 - Updated Apr 14 2014 - 1 reports

France moving ahead with biosmilar substitution

New legislation in France would allow retail pharmacists there to become the first in Europe to be able to supply patients with biosimilar versions of the biologic drug indicated on the prescription. The new rule, contained within Article 47 of this year’s ... [Published Pharma Times - Apr 13 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

Mickelson's PGA Standing vs. Enbrel's DTC Spending

Phil Mickelson, 5-over, missed the cut at the Masters this year. Bummer!Because of that, you might not see more Enbrel ads featuring Mickelson who is a hired gun - er, celebrity spokesperson - for the Enbrel brand (see "Amgen Blows Its Marketing Budget ... [Published Pharma Marketing Blog - Apr 12 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 5 reports

Drugs stolen in van raid

Thursday, 03 April 2014Warning: The stolen drugs could kill because they have been taken out of controlled environmentTHIEVES made off with thousands of pounds worth of lethal drugs from a parked van in Edmonton yesterday.Two men, described as eastern ... [Published North London Press Today - Apr 03 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 2 reports

Oral Tofacitinib Not Inferior to Etanercept for Psoriasis

DENVER — For the first time, a phase 3 trial has demonstrated that an oral small-molecule inhibitor is noninferior to a biologic agent for the treatment of psoriasis.The study pitted tofacitinib, a novel oral Janus kinase inhibitor, against the anti-TNF ... [Published General Medicine eJournal - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

Pfizer announces encouraging results from Phase III plaque psoriasis study

Pfizer Inc. has announced results from OPT Compare, a Phase III study of tofacitinib, the first in a new class of treatment, oral Janus kinase, or JAK, inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with ... [Published Individual.com - Mar 24 2014]
First reported Mar 21 2014 - Updated Mar 22 2014 - 3 reports

FDA approves Celgene's Otezla for psioratic arthritis

Just as the American Association of Dermatology opens its doors in Denver, Celgene Corp has been boosted by a green light from US regulators for Otezla as a treatment for psoriatic arthritis.The US Food and Drug Administration has approved Otezla (apremilast), ... [Published Pharma Times - Mar 22 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 2 reports

Pfizer Announces Results Of OPT Compare Phase 3 Study Of Tofacitinib

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (NYSE:PFE) announced detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were ... [Published FinanzNachrichten.de - Mar 22 2014]
First reported Mar 21 2014 - Updated Mar 22 2014 - 4 reports

Novartis announces start of new secukinumab (AIN457) versus Stelara® (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014 (NOVARTIS)

NOVARTISCompany : NOVARTIS ISIN : CH0012005267 Compartment : OtherDocument type : Permanent Information Releases / General Company News Wire : Thomson Reuters ONEPublication date : 3/21/2014 7:15:00 AMNovartis announces start of new secukinumab (AIN457) ... [Published WorldRegInfo - Mar 21 2014]

Quotes

"' This could manifest, behaviorally, via magnified antioxidant and anti-inflammatory activity, reduction of intestinal permeability and the detrimental effects of LPS, improved glycemic control, positive influence on nutritional status (and therefore neurotransmission and neuropeptide production), direct production of GABA, and other bioactive chemicals, as well as a direct role in gut-to-brain communication via a beneficial shift in the intestinal microbiota itself.' In this way, we use bacteria to modify our own bacteria and subsequently dampen inflammatory signals."
The following quote was obtained by the news editors from the background information supplied by the inventors: "The present disclosure relates to an anti-tumor necrosis factor-alpha antibody (TNF-.alpha.), and in particular relates to a humanized monoclonal antibody which is capable of highly neutralizing tumor necrosis factor-alpha, and an amino acid sequence thereof."
...Charlotta Enerback from Linkoping University told Reuters Health by email. "The total lack of change in systemic levels surprised me. That the levels were lower after systemic treatment was more expected."

More Content

All (211) | News (193) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (3) | Press Releases (1)
sort by: Date | Relevance
Buffett And Hedge Funds Love These 3 Stocks [Published Yahoo! Finance - 10 hours ago]
The Efficacy of Anti-TNF Agents for Ulcerative ... [Published Diabetes Care - 14 hours ago]
Earnings Roundup: Johnson & Johnson Results Are... [Published Motley Fool - Apr 17 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Apr 17 2014]
Company Update: Pfizer Inc (NYSE:PFE) – Teva se... [Published Jutia Group - Apr 17 2014]
Earnings Primer: What's on Deck for Amgen Inc. ... [Published Motley Fool - Apr 17 2014]
Psychoneuroimmunology—How Inflammation Affects ... [Published Mercola - Apr 17 2014]
Patent Issued for Humanized Anti-Human Tumor Ne... [Published HispanicBusiness.com - Apr 17 2014]
Baxter's latest bleeding drug hits the mark in ... [Published FierceBiotech - Apr 16 2014]
Live Viral Vaccines in Immunocompromised Patients [Published Diabetes Care - Apr 16 2014]
Cancer Risk With Adalimumab in Crohn's Disease [Published General Medicine eJournal - Apr 16 2014]
The Skin You're In [Published EverydayHealth.com - Apr 15 2014]
Chinese Thunder God Herb Works as Well as Pain ... [Published Atlanta Journal And Constitution - Apr 15 2014]
Monoclonal antibodies in rheumatoid arthritis: ... [Published Bionity.com - Apr 15 2014]
Systemic Treatment and Cardiovascular Risk Mark... [Published American Journal of Public Health - Apr 15 2014]
Biotech firms, investors biding time for breakt... [Published GantDaily.com - Apr 14 2014]
Top 10 Wealthiest Athletes: Worldwide Endorseme... [Published Wall St. Cheat Sheet - Apr 14 2014]
France moving ahead with biosmilar substitution [Published Pharma Times - Apr 13 2014]
Mickelson's PGA Standing vs. Enbrel's DTC Spending [Published Pharma Marketing Blog - Apr 12 2014]
Rheumatoid arthritis market reports several of ... [Published PR inside - Apr 11 2014]
Effects of a biologic agent in a patient with r... [Published 7thSpace - Apr 11 2014]
Humira Tops PMLive's 50 Biggest Pharma Brands 2... [Published Pharmaceutical Online - Apr 10 2014]
'It's Okay, Baby, Walk to Mama': A Toddler's Ar... [Published EverydayHealth.com - Apr 10 2014]
3 Top-Ranked Biotech Stocks on the Rebound [Published Zacks.com - Apr 10 2014]
Researchers Submit Patent Application, "Biodegr... [Published HispanicBusiness.com - Apr 10 2014]
Humira still the biggest pharma brand [Published PMLive - Apr 09 2014]
Treatment of RA With Etanercept With Reference ... [Published General Medicine eJournal - Apr 09 2014]
Do We Need a Patient Satisfaction Score? [Published General Medicine eJournal - Apr 09 2014]
Amgen: Management's History Of Shareholder Frie... [Published Seeking Alpha - Apr 08 2014]
Adult-Onset Still's Disease [Published MedIndia - Apr 07 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Top 10 Wealthiest Athletes: Worldwide Endorseme... [Published Wall St. Cheat Sheet - Apr 14 2014]
Source: Thinkstock It’s an open secret that the real money in sports isn’t in the team contract or the winnings, but in the endorsement deals. This is ever since Honus Wagner first signed on with Hillerich & Bradsby in 1905, putting his replicated ...
Mickelson's PGA Standing vs. Enbrel's DTC Spending [Published Pharma Marketing Blog - Apr 12 2014]
Phil Mickelson, 5-over, missed the cut at the Masters this year. Bummer!Because of that, you might not see more Enbrel ads featuring Mickelson who is a hired gun - er, celebrity spokesperson - for the Enbrel brand (see "Amgen Blows Its Marketing Budget ...
A Second Lawsuit Tests the BPCIA Biosimilars “P... [Published FDA Law Blog - Apr 02 2014]
By Kurt R. Karst –Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District Court for the District of Massachusetts seeking a judgment with respect ...
CRMO "Chronic Recurrent Multifocal Osteomyelitis" [Published HealthBoards - Apr 01 2014]
Our 11 year old daughter was diagnosed with CRMO this past October. It started out in her knees and has spread to new places. She's been on Methotrexate since last year and started Enbrel injections in February with no luck. She just started the Humira ...
Pfizer Announces Detailed Results of OPT Compar... [Published Business Wire Health News - Mar 22 2014]
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which ...
1 2 3

Press Releases

sort by: Date | Relevance
Coherus maakt bekend dat CHS-0214 (Proposed Eta... [Published PR Newswire - Oct 29 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.